Virgin Money UK PLC Publication of Suppl.Prospcts (8181M)
May 13 2020 - 11:01AM
UK Regulatory
TIDMVMUK TIDM91XR
RNS Number : 8181M
Virgin Money UK PLC
13 May 2020
VIRGIN MONEY UK PLC
(Company)
LEI: 213800ZK9VGCYYR6O495
CLYDESDALE BANK PLC
(Bank)
LEI: NHXOBHMY8K53VRC7MZ54
13 May 2020
Publication of Supplement to the Base Prospectus (the
"Supplement")
The following Supplement has been approved by the Financial
Conduct Authority and is available for viewing:
First Supplement dated 13 May 2020 relating to the Base
Prospectus dated 5 February 2020 for the Virgin Money UK PLC and
Clydesdale Bank PLC GBP10,000,000,000 Global Medium Term Note
Programme
Please read the disclaimer below "Disclaimer - Intended
Addressees" before attempting to access this service, as your right
to do so is conditional upon complying with the requirements set
out below.
To view the full document, please paste the following URL into
the address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/8181M_1-2020-5-13.pdf
A copy of the above document has been submitted to the National
Storage Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Announcement authorised for release by Lorna McMillan, Group
Company Secretary.
Enquiries
Investors and Analysts
Andrew Downey +44 203 216 2694
------------------------------------
Head of Investor Relations +44 7823 443150
------------------------------------
andrew.downey@virginmoneyukplc.com
------------------------------------
Company Secretary
------------------------------------
Lorna McMillan + 44 7834 585436
------------------------------------
Group Company Secretary lorna.mcmillan@virginmoneyukplc.com
------------------------------------
Media Relations
------------------------------------
Press Office 0800 066 5998
------------------------------------
press.office@virginmoneyukplc.com
------------------------------------
DISCLAIMER - INTENDED ADDRESSEES
IMPORTANT: You must read the following before continuing: The
following applies to the Supplement available by clicking on the
link above, and you are therefore advised to read this carefully
before reading, accessing or making any other use of the
Supplement. In accessing the Supplement, you agree to be bound by
the following terms and conditions, including any modifications to
them, any time you receive any information from us as a result of
such access.
THE SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS
PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER.
THE SUPPLEMENT MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO
PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE
ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES ACT") OR WITHIN THE UNITED STATES TO QIBs (AS
DEFINED BELOW) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES
ACT ("RULE 144A"). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF
THE SUPPLEMENT IN WHOLE OR IN PART IS PROHIBITED. FAILURE TO COMPLY
WITH THIS NOTICE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR
THE APPLICABLE LAWS OF OTHER JURISDICTIONS.
NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF
SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO
SO. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE
PROSPECTUS RELATING TO THE GBP10,000,000,000 GLOBAL MEDIUM TERM
NOTE PROGRAMME OF THE COMPANY AND THE BANK (DATED 5 FEBRUARY 2020
THE "BASE PROSPECTUS") HAVE NOT BEEN, AND WILL NOT BE, REGISTERED
UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OR
OTHER JURISDICTION OF THE UNITED STATES. ANY NOTES ISSUED OR TO BE
ISSUED PURSUANT TO THE BASE PROSPECTUS MAY NOT BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH RULE
144A UNDER THE SECURITIES ACT TO PERSONS REASONABLY BELIEVED TO BE
QUALIFIED INSTITUTIONAL BUYERS (EACH A "QIB") WITHIN THE MEANING OF
RULE 144A OR (2) IN AN OFFSHORE TRANSACTION TO A PERSON THAT IS NOT
A U.S. PERSON IN RELIANCE ON REGULATION S UNDER THE SECURITIES
ACT.
The Supplement must be read in conjunction with the Base
Prospectus which comprises a prospectus for the purposes of the
Prospectus Regulation (Regulation (EU) 2017/1129).
Please note that the information contained in the Supplement and
the Base Prospectus may be addressed to and/or targeted at persons
who are residents of particular countries (specified in the Base
Prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom
the offer contained in the Supplement and the Base Prospectus is
not addressed. Prior to relying on the information contained in the
Supplement and the Base Prospectus you must ascertain from the
Supplement and the Base Prospectus (as applicable) whether or not
you are part of the intended addressees of the information
contained therein.
Confirmation of your Representation: In order to be eligible to
view the Supplement or make an investment decision with respect to
any Notes issued or to be issued pursuant to the Base Prospectus,
you must be (A) a person other than a U.S. person (within the
meaning of Regulation S under the Securities Act); or (B) a QIB
that is acquiring the securities for its own account or for the
account of another QIB. By accessing the Supplement and the Base
Prospectus, you shall be deemed to have represented that you and
any customers you represent are not a U.S. person (as defined in
Regulation S to the Securities Act) or that you are a QIB, and that
you consent to delivery of the Base Prospectus and any supplements
thereto via electronic publication.
You are reminded that the Supplement has been made available to
you on the basis that you are a person into whose possession the
Supplement may be lawfully delivered in accordance with the laws of
the jurisdiction in which you are located and you may not, nor are
you authorised to, deliver the Supplement to any other person.
The Supplement and the Base Prospectus do not constitute, and
may not be used in connection with, an offer or solicitation in any
place where offers or solicitations are not permitted by law. If a
jurisdiction requires that the offering be made by a licensed
broker or dealer and the underwriters or any affiliate of the
underwriters is a licensed broker or dealer in that jurisdiction,
the offering shall be deemed to be made by the underwriters or such
affiliate on behalf of the Company or the Bank in such
jurisdiction. Under no circumstances shall the Supplement and the
Base Prospectus constitute an offer to sell, or the solicitation of
an offer to buy, nor shall there be any sale of any Notes issued or
to be issued pursuant to the Supplement or the Base Prospectus, in
any jurisdiction in which such offer, solicitation or sale would be
unlawful.
The Supplement has been made available to you in an electronic
form. You are reminded that documents transmitted via this medium
may be altered or changed during the process of electronic
transmission and consequently none of the Company, the Bank, its
advisers or any person who controls the Company, the Bank or any
director, officer, employee or agent of the Company or the Bank or
affiliate of any such person accepts any liability or
responsibility whatsoever in respect of any difference between the
Supplement made available to you in electronic format and the hard
copy version available to you on request from the Company or the
Bank.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PSPGPURCAUPUGCW
(END) Dow Jones Newswires
May 13, 2020 11:01 ET (15:01 GMT)
Ve Bionic Etf (LSE:CYBG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ve Bionic Etf (LSE:CYBG)
Historical Stock Chart
From Jul 2023 to Jul 2024